InsidersTradesSigma
Total declarations
Companies
▲ Purchases (16 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
16
Disclosed sells
1
T+90 hit rate
33%
T+90 mean return
+7.2%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Mott David M. Director active across 5 companies, notably Epizyme, Inc.. In total, 42 disclosures have been recorded. Split: 16 buys · 1 sell. Total volume traded: €10.1m. Activity tracked since 11 June 2021. The latest transaction was disclosed on 20 February 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Mott David M
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations42 total
20,282 sharesCommon StockSEC:0001219871-26-000003:0
26,455 sharesCommon StockSEC:0001219871-26-000003:1
333,333 shares@ US$5.83918.6% of flowCommon StockSEC:0001610717-26-000066:0
Canonical exit: 21 May 2026 (T+90)
23,546 sharesCommon StockSEC:0001104659-26-001368:0
31,163 shares0Common StockSEC:0001628280-25-032727:0
200,000 shares@ US$3.62948.7% of flowCommon StockSEC:0001628280-25-032226:0
Canonical exit: 14 Sept 2025 (T+90)
10,420 shares0Common StockSEC:0001593968-25-000758:0
200,000 shares@ US$3.68639.8% of flowCommon StockSEC:0001628280-25-030848:0
Canonical exit: 7 Sept 2025 (T+90)
100,000 shares@ US$3.29124.9% of flowCommon StockSEC:0001628280-25-026573:0
Canonical exit: 13 Aug 2025 (T+90)
381,377 shares@ US$4.22423.9% of flowCommon StockSEC:0001628280-25-022357:0
Canonical exit: 31 Jul 2025 (T+90)
77,729 shares@ US$5.00126.2% of flowCommon StockSEC:0001628280-25-008296:0
Canonical exit: 25 May 2025 (T+90)
199,000 shares@ US$4.988316.0% of flowCommon StockSEC:0001628280-25-002226:0
Canonical exit: 21 Apr 2025 (T+90)
100,000 shares@ US$0.550.9% of flowCommon StockSEC:0001628280-24-052533:0
213,300 shares@ US$4.672216.2% of flowCommon StockSEC:0001628280-24-052363:0
Canonical exit: 19 Mar 2025 (T+90)
215,868 shares@ US$4.616715.7% of flowCommon StockSEC:0001628280-24-047919:0
Canonical exit: 11 Feb 2025 (T+90)
17,322 shares0Common StockSEC:0001628280-24-028594:0
6,670 shares0Common StockSEC:0001593968-24-000861:0
8,810 shares0Common StockSEC:0001104659-24-001358:0
15,873 shares0Common StockSEC:0001104659-23-106831:0
6,079 shares0Common StockSEC:0001104659-23-078749:0
25,510 shares0Common StockSEC:0001628280-23-022554:0
3,100 sharesCommon StockSEC:0001209191-23-036757:0
14,467 shares0Common StockSEC:0001104659-23-070358:0
4,866 shares0Common StockSEC:0001104659-23-042242:0
567,000 shares@ US$1.764816.1% of flowCommon StockSEC:0001567619-22-020554:0
Canonical exit: 15 Feb 2023 (T+90)
25 of 42 declarations
About Mott David M
MOTT DAVID M is a Director of Ardelyx, INC., Epizyme, Inc., Mersana Therapeutics, Inc., NOVAVAX INC and IMARA Inc. The record shows 42 filings in total, and across the recent filings available from 2016-01-12 to 2026-06-18, buys amount to EUR 8923555 and sells to EUR 1226183, with the transaction nature listed as Attribution.
